Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Replimune Group, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Replimune Group, Inc. return tang equity for the quarter ending 2026-06-30 was -281.14%, a change of -197.92% year-over-year.
  • Replimune Group, Inc. return tang equity for the quarter ending 2026-03-31 was -188.94%, a change of -129.47% year-over-year.
  • Replimune Group, Inc. return tang equity for the quarter ending 2025-12-31 was -149.55%, a change of -102.23% year-over-year.
  • Replimune Group, Inc. return tang equity for the quarter ending 2025-09-30 was -117.82%, a change of -61.98% year-over-year.
  • Replimune Group, Inc. return tang equity for fiscal 2026 was -188.94%, a change of -129.47% from fiscal 2025.
  • Replimune Group, Inc. return tang equity for fiscal 2025 was -59.47%, a change of -1.85% from fiscal 2024.
  • Replimune Group, Inc. return tang equity for fiscal 2024 was -57.62%, a change of -26.23% from fiscal 2023.
  • Replimune Group, Inc. return tang equity for fiscal 2023 was -31.39%, a change of -2.68% from fiscal 2022.
Available history
2017-03-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-281.14%-$297.01M$105.65M
2026-03-31-188.94%-$313.94M$166.16M
2025-12-31-149.55%-$314.85M$210.54M
2025-09-30-117.82%-$310.26M$263.34M
2025-06-30-83.22%-$280.22M$336.72M
2025-03-31-59.47%-$247.3M$415.84M
2024-12-31-47.32%-$228.24M$482.37M
2024-09-30-55.84%-$213.02M$381.46M
2024-06-30-51.59%-$220.01M$426.45M
2024-03-31-57.62%-$215.79M$374.51M
2023-12-31-49.81%-$209.96M$421.54M
2023-09-30-42.68%-$198.53M$465.17M
2023-06-30-35.33%-$181.59M$514.03M
2023-03-31-31.39%-$174.28M$555.29M
2022-12-31-26.33%-$156.74M$595.35M
2022-09-30-38.20%-$146.73M$384.07M
2022-06-30-32.41%-$132.98M$410.26M
2022-03-31-28.70%-$118.04M$411.23M
2021-12-31-24.65%-$107.84M$437.51M
2021-09-30-21.85%-$99.95M$457.41M
2021-06-30-18.93%-$90.69M$479.02M
2021-03-31-16.22%-$80.87M$498.73M
2020-12-31-14.56%-$75.16M$516.2M
2020-09-30-26.61%-$69.57M$261.39M
2020-06-30-21.82%-$60.61M$277.81M
2020-03-31-28.64%-$52.63M$183.72M
2019-12-31-22.01%-$43.49M$197.57M
2019-09-30-28.99%-$34.98M$120.64M
2019-06-30-23.28%-$30.3M$130.15M
2019-03-31-22.37%-$30.83M$137.86M
2018-12-31-21.66%-$31.03M$143.24M
2018-09-30-18.47%-$27.71M$150.04M
2018-06-3066.94%-$25.91M-$38.7M
2018-03-3169.17%-$19.41M-$28.07M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-03-31-188.94%-$313.94M$166.16M
2025-03-31-59.47%-$247.3M$415.84M
2024-03-31-57.62%-$215.79M$374.51M
2023-03-31-31.39%-$174.28M$555.29M
2022-03-31-28.70%-$118.04M$411.23M
2021-03-31-16.22%-$80.87M$498.73M
2020-03-31-28.64%-$52.63M$183.72M
2019-03-31-22.37%-$30.83M$137.86M
2018-03-3170.19%-$19.7M-$28.07M
2017-03-3166.90%-$7.7M-$11.52M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B